Last updated: February 20, 2026
What is the market position of EVENITY?
EVENITY (romosozumab) is a monoclonal antibody developed by Amgen, approved for the treatment of osteoporosis in postmenopausal women at high fracture risk. It operates as a dual-action agent that increases bone formation and decreases bone resorption. Since its approval by the U.S. FDA in April 2019 and subsequent European approval in July 2020, EVENITY has positioned itself as an alternative to traditional antiresorptive treatments.
How has the market for osteoporosis treatments evolved?
The osteoporosis treatment market has grown due to aging populations worldwide. The global osteoporosis market size was valued at approximately USD 8 billion in 2021 and is projected to reach USD 13 billion by 2030, expanding at a CAGR of 5.2% ([1]).
Traditional treatments focus on antiresorptive therapies such as bisphosphonates. Anabolic agents like EVENITY offer a new mechanism, targeting a niche for high-risk patients. However, the market penetration of EVENITY faces limitations including competition, safety concerns, and prescribing patterns.
What are the sales figures and revenue estimates for EVENITY?
2022 Financial Performance
- Global sales: Approximate USD 450 million
- Key markets: U.S., Europe, Japan
- U.S. share: 65% of total sales
2023-2025 Projections
- Estimated sales growth: Cumulative CAGR of 20% (USD 580 million in 2023, USD 700 million in 2024)
- Break-even point: Not reached; profits depend on increased adoption and market expansion
Market Share
- In the U.S., it holds an estimated 12% of the osteoporosis drug market
- Competing against bisphosphonates, denosumab, and anabolic agents like teriparatide
Pricing Strategy
- Cost per dose: USD 2,000
- Treatment duration: 12 doses over 12 months
- Insurance reimbursement: Major influence on uptake
How are competitive factors affecting market dynamics?
Main Competitors
| Drug |
Type |
Market Share (2022) |
Approval Date |
Key Advantages |
Limitations |
| Bisphosphonates |
Antiresorptive |
55% |
1990s |
Well-established, lower cost |
Compliance issues, contraindications |
| Denosumab (Prolia) |
Antiresorptive |
20% |
2010 |
Subcutaneous, no renal concerns |
Cost, hypocalcemia risk |
| Teriparatide |
Anabolic |
8% |
2002 |
Bone-building effect |
Cost, injections daily |
| EVENITY |
Anabolic & antiresorptive |
12% |
2019 |
Dual action, shorter treatment course |
Safety concerns, high price |
Safety Profile and Regulatory Considerations
- Cardiovascular events: Signal led to warnings in some regions
- Fracture prevention efficacy: Demonstrated in clinical trials, but long-term data limited
- Commercial hesitancy: Due to safety concerns and competition
What are the key factors influencing future financial performance?
- Market expansion: Increase adoption in European and Asian markets
- Pricing and reimbursement policies: Favorable reimbursement boosts sales
- Regulatory decisions: Label updates and safety approvals directly impact market access
- Clinical developments: New studies confirming safety/effectiveness can increase prescriptions
- Competitor pipeline: Emerging drugs may erode market share
What is the outlook for EVENITY’s financial trajectory?
EVENITY’s revenue growth will hinge on market acceptance, safety profile improvements, and expansion into new territories. While profit margins are constrained by high manufacturing and development costs, strategic positioning targeting high-risk, treatment-resistant patients supports moderate growth projections.
Potential upside exists if lifecycle management strategies include combination therapies or new indication approvals. Conversely, safety concerns and competitive pressure limit aggressive growth.
Key Market Drivers
- Increasing elderly population globally
- Rising awareness of osteoporosis and fracture risk
- Favorable shifts in treatment guidelines favoring anabolic agents for certain patient subsets
- Amgen’s marketing efforts and physician education
Challenges and Risks
- Safety warnings limiting prescribing
- High treatment costs and reimbursement hurdles
- Competitive landscape with well-established therapies
- Regulatory delays or restrictions
Conclusion
EVENITY’s financial trajectory remains cautiously optimistic. Its innovation in dual-action osteoporosis treatment makes it a compelling option for high-risk patients, but market share expansion depends heavily on safety profile, pricing strategies, and regulatory environment. The drug is positioned for slow growth aligned with demographic trends and evolving clinical guidelines.
Key Takeaways
- EVENITY generated approximately USD 450 million in 2022, with a growth CAGR of 20% forecasted through 2024.
- Markets outside the U.S. are underserved, representing a key expansion opportunity.
- Competition from bisphosphonates and denosumab remains strong; safety concerns hinder broader adoption.
- Pricing, reimbursement policies, and safety profile improvements strongly influence its growth trajectory.
- Long-term profitability is uncertain but offset by demographic trends favoring osteoporosis therapies.
FAQs
1. How does EVENITY compare to other osteoporosis treatments?
EVENITY offers a dual mechanism as an anabolic and antiresorptive agent, providing a shorter treatment course compared to drugs like teriparatide. However, safety profiles and costs limit its widespread use relative to bisphosphonates.
2. What factors could accelerate EVENITY’s market penetration?
Enhanced safety data, expanded approvals, favorable reimbursement policies, and increased awareness among physicians could boost adoption.
3. What are key barriers to EVENITY’s growth?
Safety concerns (particularly cardiovascular risk signals), high treatment costs, and entrenched market leadership of bisphosphonates and denosumab.
4. Which geographic regions present the largest growth opportunities?
Europe and Asia offer significant potential, driven by aging populations and lower penetration of innovative therapies.
5. How do regulatory decisions impact the financial outlook for EVENITY?
Regulatory approvals or restrictions directly influence the drug’s market access and revenue potential, especially if safety signals affect labeling or prescribing restrictions.
References
[1] Grand View Research. (2022). Osteoporosis Drugs Market Size, Share & Trends Analysis Report.
